科研動(dòng)態(tài)

為評估重組禽流感病毒二價(jià)滅活疫苗（H5N1 Re-8株和H7N9 H7-Re1株）對雉的免疫保護(hù)效果，選取30日齡的雉，按照免疫程序首免后21 d，加強(qiáng)免疫1次，分別于接種前和接種后定期采血，分離血清，檢測H5、H7亞型HI抗體滴度。結(jié)果顯示，免疫前，雉血清中H5、H7亞型HI抗體滴度均為0；免疫后 14 d，H5和H7亞型抗體平均滴度分別達(dá)到7.0log2和7.07log2，49 d后平均滴度達(dá)到峰值，分別為8.04log2和9.20log2；H5亞型免疫有效期可達(dá)105 d以上，H7亞型可達(dá)189 d以上。結(jié)果表明，重組禽流感病毒二價(jià)滅活疫苗（H5N1 Re-8株+H7N9 H7-Re1株）對雉具有良好的免疫保護(hù)效果且安全性良好，但疫苗免疫49 d后，H5、H7抗體效價(jià)逐漸下降，133 d后明顯下降，群體免疫合格率低于70%，因此生產(chǎn)中推薦，30日齡首免后，51日齡和5月齡各加強(qiáng)免疫1次。本研究為珍稀禽的禽流感免疫疫苗選擇和程序制定提供了參考。

Study on the Immune Effects of Recombinant Avian Influenza VirusBivalent Inactivated Vaccines（H5N1 Re-8+H7N9 H7-Re1 Strain）in Pheasants

In order to evaluate theimmune effects of recombinant avian influenza virus（A/V） bivalentinactivated vaccines（H5N1 Re-8+H7N9 H7-Re1 strain）in pheasants，30-day-old pheasants wereselected for first vaccination，followed by boostervaccination after 21 days according to immune procedures，and their blood samples were collected regularly before and aftervaccination respectively to test the titers of HI antibodies against H5 and H7subtype AIV. The results showed that，before vaccination，the titers of HI antibodies against H5 and H7 subtypes in the serumof pheasants were 0；and the average titers of H5 and H7subtypes could reach to 7.0log2 and 7.07log2 respectively after 14 days，then increased to the peak after 49 days，whichwere 8.04log2 and 9.20log2 respectively；the immunevalidity for H5 subtype AIV could remain for 105 days or above，and that for H7 subtype could be up to 189 days，which indicated the immune effects and security of bivalentinactivated vaccines were good. However，the titers ofH5 and H7 antibodies decreased gradually after 49 days of vaccination，then decreased significantly after 133 days，andthe qualified rates at herd level was less than 70%. Therefore，it was suggested that，after the firstimmunization at the age of 30 days，the reinforcedvaccination should be carried out at the ages of 51 days and 5 monthsrespectively. In conclusion，the research would providesome references for selecting vaccines（for rare andprecious birds）and developing relevant procedures.

全文下載鏈接：http://kns.cnki.net/KCMS/detail/37.1246.S.20190802.1405.034.html